Delaware Clinical and Translational Research ACCEL Program

特拉华州临床和转化研究 ACCEL 计划

• 批准号: 10885455
• 负责人: Gregory E Hicks
• 金额: $ 20.91万
• 依托单位: UNIVERSITY OF DELAWARE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-25 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10885455
• 关键词: Acceleration; Adult; African American; Agreement; American; Area; Asian; Award; Biometry; Black race; Budgets; Caucasians; Cessation of life; Child Health; Childhood; Clinical; Clinical Research; Communities; Community Outreach; Delaware; Development; Epidemiology; Equity; Ethnic Origin; Evaluation; Funding; Goals; Grant; Growth; Health; Health Promotion; Healthcare; Healthcare Systems; Hispanic; Hospitals; Infrastructure; Institution; Intention; Investments; Learning; Letters; Malignant Neoplasms; Mission; Modeling; Modification; Native Americans; Obesity; Outreach Research; Pharmaceutical Preparations; Pilot Projects; Population; Population Heterogeneity; Population Research; Recommendation; Research Design; Research Personnel; Rural; Scientist; Societies; Structure; System; Time; Training; Translational Research; Universities; Work; Writing; clinical infrastructure; community engagement; design; health care quality; health equity; health inequalities; hospitalization rates; improved; innovation; member; multiple chronic conditions; population health; programs; racial diversity; recruit; translational research program; translational scientist

ABSTRACT- OVERALL This proposal is a competitive renewal of the Institutional Development Award Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54) grant originally awarded in September 2013 to the University of Delaware. The ACCEL CTR Program, has completed nine years of funding at the time of this application. During our third funding cycle (ACCEL3), our consortium will consist of four partners: University of Delaware (UD)—the lead institution; Nemours Children’s Health (Nemours); Christiana Care Health System (CCHS), the largest health care system in Delaware; and Delaware State University (DSU), an American historically Black, public university that joined our consortium during the last competitive renewal. Over the past nine years, ACCEL has established an exceedingly strong network and infrastructure for clinical and translational (C&T) research within the state of Delaware; and, we are now poised and ready to continue our growth trajectory. While we will continue with the activities that have made us successful, we will have a sharper focus on building sustainable infrastructure across the state that can continue to thrive and mature for years to come. And, we will focus on creating a scientific culture focused, not only, on improving the health of Delawareans, but doing so through a lens of health equity. In our mission to establish a cadre of successful C&T scientists in DE, we will use various approaches to promote full consideration of how their work impacts the needs of all members of society, from design to study implementation to dissemination of findings. And, we will have a much greater focus on building a bi-directional relationship between our scientists and the community so that we can have a greater impact on Delawareans. Delaware is an ideal state for a CTR grant as it represents the whole of the USA in a compact form. The population of Delaware (~970,000) mirrors the US population in urban-to-rural citizen ratio and ethnic/racial diversity, with 23% African American, 62% Caucasian, 10% Hispanic, 4% Asian and 1% Native American. Thus, studies involving a cross-section of Delaware can be generalizable to populations nationally. The dominance of adult (CCHS) and pediatric (Nemours) hospital systems, which serve at least 85% of the residents of the state, provides a unique opportunity to treat the state of Delaware as a model for examining how healthcare changes can impact population health. The overarching goal of the ACCEL CTR Program is to create a unified Delaware Clinical and Translational Research Community (inclusive of investigators and community members) that breaks down existing barriers, capitalizes on the unique strengths of its partners to establish infrastructure and accelerates the creation of equitable solutions that improve the health of all Delawareans and all Americans.

摘要--总体 这项提案是机构发展奖计划基础设施的竞争性续签 临床和转化研究(IDEA-CTR)(U54)拨款最初于2013年9月授予 特拉华大学。Accel CTR计划已经完成了九年的资助 这个应用程序。在我们的第三个融资周期(ACCEL3)，我们的财团将由四个合作伙伴组成： 特拉华大学(UD)--牵头机构；Nemour儿童健康(Nemour)；克里斯蒂安娜 护理保健系统(CCHS)，特拉华州最大的医疗保健系统；特拉华州州立大学 (DSU)，一所美国历史上的黑人公立大学，在去年加入了我们的财团 竞争性更新。在过去的九年里，Accel建立了一个非常强大的网络 以及特拉华州内临床和转化(C&T)研究的基础设施； 现在已经做好准备，准备继续我们的增长轨迹。我们将继续开展这些活动， 使我们取得成功，我们将更加专注于在整个地区建立可持续的基础设施 一个能够在未来几年继续蓬勃发展和成熟的国家。而且，我们将专注于创建一个 科学文化不仅关注于改善特拉华州人的健康，而且还通过一个镜头来做到这一点 健康公平的问题。在我们的使命是在DE建立一支成功的C&T科学家队伍，我们将使用 促进充分考虑其工作如何影响联合国所有成员的需要的各种方法 社会，从设计到研究实施，再到研究成果的传播。而且，我们将会有很多 更加注重在我们的科学家和社区之间建立双向关系，以便 我们可以对特拉华州人产生更大的影响。特拉华州是CTR拨款的理想州，因为它 以紧凑的形式代表整个美国。特拉华州的人口(约970,000人)反映了 美国人口的城乡公民比例和种族/种族多样性，其中非裔美国人占23%，非裔美国人占62% 高加索人，10%的西班牙人，4%的亚洲人和1%的印第安人。因此，涉及横截面的研究 特拉华州可以推广到全国人口。成人(CCHS)和儿童(CCHS)的优势 (Nemour)医院系统为该州至少85%的居民提供服务，提供了独特的 将特拉华州视为研究医疗改革如何影响的典范的机会 人口健康。Accel CTR计划的首要目标是创建一个统一的特拉华州 临床和转译研究社区(包括研究人员和社区成员) 打破现有障碍，利用合作伙伴的独特优势建立 基础设施，并加快制定公平的解决办法，改善所有人的健康 特拉华州人和所有美国人。

项目成果

Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review.

• DOI: 10.1007/s40256-015-0131-6
• 发表时间: 2015-12
• 期刊: American journal of cardiovascular drugs : drugs, devices, and other interventions
• 作者: Fanari Z;Weiss S;Weintraub WS
• 通讯作者: Weintraub WS

Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.

用于成人和儿童癌症治疗的细胞周期抑制剂化疗的开发。

• DOI: 10.1158/0008-5472.can-17-2782
• 发表时间: 2018-01-15
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: Mills CC;Kolb EA;Sampson VB
• 通讯作者: Sampson VB

Magnetic resonance imaging measures of decreased aortic strain and distensibility are proportionate to insulin resistance in adolescents with type 1 diabetes mellitus.

• DOI: 10.1111/pedi.12241
• 发表时间: 2015-03
• 期刊: Pediatric diabetes
• 影响因子: 3.4
• 作者: McCulloch MA;Mauras N;Canas JA;Hossain J;Sikes KM;Damaso LC;Redheuil A;Ross JL;Gidding SS
• 通讯作者: Gidding SS

Congenitally Corrected Transposition of the Great Arteries: Fetal Diagnosis, Associations, and Postnatal Outcome: A Fetal Heart Society Research Collaborative Study.

• DOI: 10.1161/jaha.122.029706
• 发表时间: 2023-06-06
• 期刊: Journal of the American Heart Association
• 影响因子: 5.4
• 作者: Cohen J;Arya B;Caplan R;Donofrio MT;Ferdman D;Harrington JK;Ho DY;Hogan W;Hornberger LK;Jhaveri S;Killen SAS;Lindblade CL;Michelfelder E;Moon-Grady AJ;Patel S;Quezada E;Ronai C;Sanchez Mejia AA;Schidlow DN;Stiver C;Thakur V;Srivastava S
• 通讯作者: Srivastava S

Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial).

• DOI: 10.1016/j.amjcard.2013.07.034
• 发表时间: 2013-12-01
• 期刊: The American journal of cardiology
• 作者: Sedlis SP;Jurkovitz CT;Hartigan PM;Kolm P;Goldfarb DS;Lorin JD;Dada M;Maron DJ;Spertus JA;Mancini GB;Teo KK;Boden WE;Weintraub WS;COURAGE Study Investigators
• 通讯作者: COURAGE Study Investigators